Newswire (Published: Monday, June 26, 2017, Received: Thursday, June 22, 2017, 1:05:30 PM CDT)

Word Count: 505

Data on Prostate Cancer Described by Researchers at University of Toronto (Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news originating from Toronto, Canada, by NewsRx correspondents, research stated, "To make recommendations with respect to bone health and bone-targeted therapies in men with prostate cancer. A systematic review was carried out by searching MEDLINE, EMBASE and the Cochrane Library from inception to January 2016."

Our news journalists obtained a quote from the research from the University of Toronto, "Systematic reviews and randomised-controlled trials were considered for inclusion if they involved therapies directed at improving bone health or outcomes such as skeletal-related events, pain and quality of life in patients with prostate cancer either with or without metastases to bone. Therapies included medications, supplements or lifestyle modifications alone or in combination and were compared with placebo, no treatment or other agents. Disease-targeted agents such as androgen receptor-targeted and chemotherapeutic agents were excluded. Recommendations were reviewed by internal and external review groups. In men with prostate cancer receiving androgen deprivation therapy, baseline bone mineral density testing is encouraged. Denosumab should be considered for reducing the risk of fracture in men on androgen deprivation therapy with an increased fracture risk. Bisphosphonates were effective in improving bone mineral density, but the effect on fracture was inconclusive. No medication is recommended to prevent the development of first bone metastasis. Denosumab and zoledronic acid are recommended for preventing or delaying skeletal-related events in men with metastatic castration-resistant prostate cancer. Radium-223 is recommended for reducing symptomatic skeletal events and prolonging survival in men with symptomatic metastatic castration-resistant prostate cancer."

According to the news editors, the research concluded: "The recommendations represent a current standard of care that is feasible to implement, with outcomes valued by clinicians and patients."

For more information on this research see: Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline. Clinical Oncology, 2017;29(6):348-355. Clinical Oncology can be contacted at: Elsevier Science London, 84 Theobalds Rd, London WC1X 8RR, England. (Elsevier -; Clinical Oncology -

The news correspondents report that additional information may be obtained from S.M.H. Alibhai, University of Toronto, Univ Hlth Network, Dept. of Med, Toronto, ON, Canada. Additional authors for this research include K. Zukotynski, C. Walker-Dilks, U. Emmenegger, A. Finelli, S.C. Morgan, S.J. Hotte and E. Winquist (see also Oncology - Prostate Cancer).

Keywords for this news article include: Toronto, Ontario, Canada, North and Central America, Cancer, Risk and Prevention, Monoclonal Antibodies, Drugs and Therapies, Prostatic Neoplasms, Prostate Cancer, Bone Research, Biotechnology, Immunotherapy, Denosumab, Androgens, Oncology, University of Toronto.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC




Central America
North America
Northern Europe
United Kingdom


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies
            Medicinal Drugs
                  Antibody Therapy